Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2018 / N 1

Варианты течения быстропрогрессирующего гломерулонефрита: как и чем лечить
И.Г. Гордеев, В.Н. Соболева, Н.А. Волов, Ю.М. Машукова, М.А. Селезнева

Список литературы
1. Findley M, Isles C. Rapidly progressive glomerulonephritis. In: Findley M, Isles C. Clinical companion in nephrology. Glasgow: Springer International Publishing; 2015:95-98.
2. Giorgini A, Brown HJ, Sacks SH, Robson MG. Toll-like receptor-4 stimulation triggers crescentic glomerulonephritis by multiple mechanisms including a direct effect on renal cells. American Journal of Pathology 2010 Aug;177(2):644-53.
3. Hopfer H, Holzer J, Hünemörder S, Paust HJ, Sachs M, Meyer-Schwesinger C, Turner JE, Panzer U, Mittrücker HW. Characterization of the renal CD4+ T-cell response in experimental autoimmune glomerulonephritis. Kidney International 2012 Jul;82(1):60-71.
4. Turner JE, Krebs C, Tittel AP, Paust HJ, Meyer-Schweising C, Bennstein SB, Steinmetz OM, Prinz I, Magnus T, Korn T, Stahl RAK, Kurts C, Panzer U. IL-17A production by renal γδ T cells promotes kidney injury in crescentic GN. Journals of the American Society of Nephrology 2012 Sep; 23(9):1486-95.
5. Bollée G, Flamant M, Schordan S, Fligny C, Rumpel E, Milon M, Schordan E, Sabaa N, Vandermeersch S, Galaup A, Rodenas A, Casal I, Sunnarborg SW, Salant DJ, Kopp JB, Threadgill DW, Quaggin SE, Dussaule JC, Germain S, Mesnard L, Endlich K, Boucheix C, Belenfant X, Callard P, Endlich N, Tharaux PL. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nature Medicine 2011 Sep;17(10):1242-50.
6. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrology Dialysis Transplantation 1997 Mar;12(3):418-26.
7. Fomegné G, Dratwa M, Wens R, Mesquita M, Van der Straaten M, Vanden HK, Fosso C. Goodpasture disease. Revue Médicale de Bruxelles 2006 May-Jun;27(3):162-6.
8. Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg–Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis & Rheumatism 2004 Feb;51(1):92-9.
9. Lane SE, Scott DG, Heaton A, Watts RA. Primary renal vasculitis in Norfolk – increasing incidence or increasing recognition? Nephrology, Dialysis, Transplantation 2000 Jan;15(1):23-7.
10. Kidney Disease: Improving Global Outcomes (KDIGO). Glomerulonephritis work group. KDIGO Clinical practice guideline for glomerulonephritis. Kidney International Supplements 2012;2(2):139-274.
11. Мухин Н.А., Шилов Е.М. Быстропрогрессирующий гломерулонефрит. В кн.: Нефрология: национальное руководство, краткое издание. Под ред. Мухина Н.А. М.: Гэотар-Медиа; 2014:210-5.
12. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New England Journal of Medicine 2010 Jul;363(3):221-32.
13. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrology, Dialysis, Transplantation 2008 Apr;23(4):1307-12.
14. Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Journal of the American Society of Nephrology 2015 Apr;26(4):976-85.
15. Bandak G, Jones BA, Li J, Yee J, Umanath K. Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy. Clinical Kidney Journal 2014 Feb;7(1):53-6.
16. Schless B, Yildirim S, Beha D, Keller F, Czock D. Rituximab in two cases of Goodpasture’s syndrome. NDT Plus 2009 Jun;2(3):225-7.
17. Shah Y, Mohiuddin A, Sluman C, Daryanani I, Ledson T, Banerjee A, Crowe A, McClelland P. Rituximab in anti-glomerular basement membrane disease. QJM 2012 Feb; 105(5):195-7.
18. Syeda UA, Singer NG, Magrey M. Anti-glomerular basement membrane antibody disease treated with rituximab: a case-based review. Seminars in Arthritis and Rheumatism 2013 Jun;42(6):567-72.
19. Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D’Cruz D.P. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013 May; 22(6):574-82.
20. Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A, García-Hernández F, Callejas-Rubio JL, Rascón J, D’Cruz D., Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA; UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmunity Reviews 2012 Mar;11(5):357-64.
21. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis & Rheumatism 2010 Jan;62(1):222-33.
22. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis & Rheumatism 2012 Apr;64(4):1215-26.
23. Silva F, Specks U, Kalra S, Hogan MC, Leung N, Sethi S, Fervenza FC. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement–a prospective, open-label pilot trial. Clinical Journal of the American Society of Nephrology 2010 Mar;5(3):445-53.
24. Liang Y, Zhang J, Liu D, Quan S, Xing G, Liu Z. Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype. Chinese Medical Journal 2014;127(1):102-08.
25. Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. Journal of the American Society of Nephrology 2007 Jul;18(7):2180-88.
26. Walsh M, Casian A, Flossmann O, Westman K, Höglund P, Pusey C, Jayne DR; European Vasculitis Study Group (EUVAS). Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney International 2013 Aug;84(2):397-402.
27. Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, Haubitz M, Merkel PA, Peh CA, Pusey C, Jayne D. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. American Journal of Kidney Diseases 2011 Apr;57(4):566-74.
28. Augusto JF, Sayegh J, Delapierre L, Croue A, Tollis F, Cousin M. Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Schönlein purpura in adults: a case series. American Journal of Kidney Diseases 2012 May;59(5):663-9.
29. McAdoo SP, Reynolds J, Bhangal G, Smith J, McDaid JP, Tanna A, Jackson WD, Masuda ES, Cook HT, Pusey CD, Tam FWK. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. Journals of the American Society of Nephrology 2014 Oct;25(10):2291-302.
30. Smith J, McDaid JP, Bhangal G, Chawanasuntorapoj R, Masuda ES, Cook HT, Pusey CD, Tam FWK. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. Journals of the American Society of Nephrology 2010 Feb;21(2):231-6.
31. Iyoda M, Shibata T, Kawaguchi M, Yamaoka T, Akizawa T. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney International 2009 May;75(10):1060-70.
32. Iyoda M, Shibata T, Wada Y, Kuno Y, Shindo-Hirai Y, Matsumoto K, Akizawa T. Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis. Nephrology, Dialysis, Transplantation 2013 Mar;28(3):576-84.
33. Wallace E, Fogo AB, Schulman G. Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis. American Journal of Kidney Diseases 2012 Jan;59(1):122-5.
34. Bontscho J, Schreiber A, Manz R.A, Schneider W, Luft FC, Kettritz R. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. American Journal of Kidney Diseases 2011 Feb;22(2):336-48.
35. Шилов Е.М., Козловская Н.Л., Коротчаева Ю.В.; Научное общество нефрологов России, Ассоциация нефрологов России. Клинические рекомендации по диагностике и лечению быстропрогрессирующего гломерулонефрита (экстракапиллярного гломерулонефрита с полулуниями). Нефрология 2015;19(6):73-82. Доступно по: https://cyberleninka.ru/article/v/klinicheskie-rekomendatsii-po-diagnostike-i-lecheniyu-bystroprogressiruyuschego-glomerulonefrita-ekstrakapillyarnogo. Ссылка активна на 22.02.2018.
References
1. Findley M, Isles C. Rapidly progressive glomerulonephritis. In: Findley M, Isles C. Clinical companion in nephrology. Glasgow: Springer International Publishing; 2015:95-98.
2. Giorgini A, Brown HJ, Sacks SH, Robson MG. Toll-like receptor-4 stimulation triggers crescentic glomerulonephritis by multiple mechanisms including a direct effect on renal cells. American Journal of Pathology 2010 Aug;177(2):644-53.
3. Hopfer H, Holzer J, Hünemörder S, Paust HJ, Sachs M, Meyer-Schwesinger C, Turner JE, Panzer U, Mittrücker HW. Characterization of the renal CD4@+ T-cell response in experimental autoimmune glomerulonephritis. Kidney International 2012 Jul;82(1):60-71.
4. Turner JE, Krebs C, Tittel AP, Paust HJ, Meyer-Schweising C, Bennstein SB, Steinmetz OM, Prinz I, Magnus T, Korn T, Stahl RAK, Kurts C, Panzer U. IL-17A production by renal γδ T cells promotes kidney injury in crescentic GN. Journals of the American Society of Nephrology 2012 Sep; 23(9):1486-95.
5. Bollée G, Flamant M, Schordan S, Fligny C, Rumpel E, Milon M, Schordan E, Sabaa N, Vandermeersch S, Galaup A, Rodenas A, Casal I, Sunnarborg SW, Salant DJ, Kopp JB, Threadgill DW, Quaggin SE, Dussaule JC, Germain S, Mesnard L, Endlich K, Boucheix C, Belenfant X, Callard P, Endlich N, Tharaux PL. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nature Medicine 2011 Sep;17(10):1242-50.
6. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrology Dialysis Transplantation 1997 Mar;12(3):418-26.
7. Fomegné G, Dratwa M, Wens R, Mesquita M, Van der Straaten M, Vanden HK, Fosso C. Goodpasture disease. Revue Médicale de Bruxelles 2006 May-Jun;27(3):162-6.
8. Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg–Strauss syndrome in a French urban multiethnic population in 2000: a capture–recapture estimate. Arthritis & Rheumatism 2004 Feb;51(1):92-9.
9. Lane SE, Scott DG, Heaton A, Watts RA. Primary renal vasculitis in Norfolk – increasing incidence or increasing recognition? Nephrology, Dialysis, Transplantation 2000 Jan;15(1):23-7.
10. Kidney Disease: Improving Global Outcomes (KDIGO). Glomerulonephritis work group. KDIGO Clinical practice guideline for glomerulonephritis. Kidney International Supplements 2012;2(2):139-274.
11. Mukhin NA, Shilov EM. Rapidly progressive glomerulonephritis. In: Nephrology: national guide, abridged version. Mukhin NA, editor-in-chief. Moscow: Geotar-Media;2014:210-5 (In Russian).
12. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New England Journal of Medicine 2010 Jul;363(3):221-32.
13. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrology, Dialysis, Transplantation 2008 Apr;23(4):1307-12.
14. Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Journal of the American Society of Nephrology 2015 Apr;26(4):976-85.
15. Bandak G, Jones BA, Li J, Yee J, Umanath K. Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy. Clinical Kidney Journal 2014 Feb;7(1):53-6.
16. Schless B, Yildirim S, Beha D, Keller F, Czock D. Rituximab in two cases of Goodpasture’s syndrome. NDT Plus 2009 Jun;2(3):225-7.
17. Shah Y, Mohiuddin A, Sluman C, Daryanani I, Ledson T, Banerjee A, Crowe A, McClelland P. Rituximab in anti-glomerular basement membrane disease. QJM 2012 Feb; 105(5):195-7.
18. Syeda UA, Singer NG, Magrey M. Anti-glomerular basement membrane antibody disease treated with rituximab: a case-based review. Seminars in Arthritis and Rheumatism 2013 Jun;42(6):567-72.
19. Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D’Cruz D.P. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013 May; 22(6):574-82.
20. Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A, García-Hernández F, Callejas-Rubio JL, Rascón J, D’Cruz D., Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA; UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmunity Reviews 2012 Mar;11(5):357-64.
21. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis & Rheumatism 2010 Jan;62(1):222-33.
22. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis & Rheumatism 2012 Apr;64(4):1215-26.
23. Silva F, Specks U, Kalra S, Hogan MC, Leung N, Sethi S, Fervenza FC. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement–a prospective, open-label pilot trial. Clinical Journal of the American Society of Nephrology 2010 Mar;5(3):445-53.
24. Liang Y, Zhang J, Liu D, Quan S, Xing G, Liu Z. Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype. Chinese Medical Journal 2014;127(1):102-08.
25. Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. Journal of the American Society of Nephrology 2007 Jul;18(7):2180-88.
26. Walsh M, Casian A, Flossmann O, Westman K, Höglund P, Pusey C, Jayne DR; European Vasculitis Study Group (EUVAS). Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney International 2013 Aug;84(2):397-402.
27. Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, Haubitz M, Merkel PA, Peh CA, Pusey C, Jayne D. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. American Journal of Kidney Diseases 2011 Apr;57(4):566-74.
28. Augusto JF, Sayegh J, Delapierre L, Croue A, Tollis F, Cousin M. Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Schönlein purpura in adults: a case series. American Journal of Kidney Diseases 2012 May;59(5):663-9.
29. McAdoo SP, Reynolds J, Bhangal G, Smith J, McDaid JP, Tanna A, Jackson WD, Masuda ES, Cook HT, Pusey CD, Tam FWK. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. Journals of the American Society of Nephrology 2014 Oct;25(10):2291-302.
30. Smith J, McDaid JP, Bhangal G, Chawanasuntorapoj R, Masuda ES, Cook HT, Pusey CD, Tam FWK. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. Journals of the American Society of Nephrology 2010 Feb;21(2):231-6.
31. Iyoda M, Shibata T, Kawaguchi M, Yamaoka T, Akizawa T. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney International 2009 May;75(10):1060-70.
32. Iyoda M, Shibata T, Wada Y, Kuno Y, Shindo-Hirai Y, Matsumoto K, Akizawa T. Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis. Nephrology, Dialysis, Transplantation 2013 Mar;28(3):576-84.
33. Wallace E, Fogo AB, Schulman G. Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis. American Journal of Kidney Diseases 2012 Jan;59(1):122-5.
34. Bontscho J, Schreiber A, Manz R.A, Schneider W, Luft FC, Kettritz R. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. American Journal of Kidney Diseases 2011 Feb;22(2):336-48.
35. Shilov EM, Kozlovskaya NL, Korotchaeva YuV; Scientific Society of Nephrologists of Russia, Association of Nephrologists of Russia. Clinical guidelines for the diagnosis and treatment of rapidly progressive glomerulonephritis (extracapillary glomerulonephritis with crescent formation). Nephrology 2015;19(6):73-82. Available from: https://cyberleninka.ru/article/v/klinicheskie-rekomendatsii-po-diagnostike-i-lecheniyu-bystroprogressiruyuschego-glomerulonefrita-ekstrakapillyarnogo Accessed 2018 Feb 22 (In Russian).
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]